Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Related MD
Benzinga's Top Initiations
MEDNAX Announces Acquisition of Large Anesthesiology Practice in New Jersey

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

Oct 2015SunTrust Robinson HumphreyMaintainsNeutral
Sep 2015Mizuho SecuritiesInitiates Coverage onBuy
Sep 2015Mizuho SecuritiesInitiates Coverage onBuy

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (MD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters